<?xml version="1.0" ?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
<listBibl>
	<bibl>. <orgName>Ministry of Health, Labour and Welfare</orgName>. <title level="m">Vital Statistics of Japan</title>. <ptr type="web">https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai18/dl/gaikyou30.pdf</ptr>. Accessed <date>25 March 2020</date>.</bibl>
	<bibl>. <orgName>National Cancer Center Japan</orgName>. <title level="m">Cancer Statistics in 2016</title>. <ptr type="web">https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2019_report.pdf</ptr>. Accessed <date>29 June 2019</date>.</bibl>
	<bibl>. <orgName>Ministry of Health, Labour and Welfare</orgName>. <title level="a">Estimated number of patients</title>. <ptr type="web">https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/dl/01.pdf</ptr>. Accessed <date>25 August 2020</date>.</bibl>
	<bibl>. <orgName>Japanese Society of Medical Oncology</orgName>. <title level="m">Guidelines for Cancer Immunotherapy</title>. <note>2nd ed.</note> <pubPlace>Tokyo, Japan</pubPlace>: <publisher>Kanehara &amp; Co., Ltd</publisher>.; <date>2019</date>.</bibl>
	<bibl>. <author>Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J, Moslehi JJ</author>. <title level="a">Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research</title>. <title level="j">Lancet Oncol</title>. <date>2020</date>;<biblScope unit="volume">21</biblScope>(<biblScope unit="issue">8</biblScope>):<biblScope unit="page">e398-e404</biblScope>. <ptr type="web">https://doi.org/10.1016/S1470-2045(20)30107-8</ptr></bibl>
	<bibl>. <author>Postow MA, Sidlow R, Hellmann MD</author>. <title level="a">Immune-related adverse events associated with immune checkpoint blockade</title>. <title level="j">N Engl J Med</title>. <date>2018</date>;<biblScope unit="volume">378</biblScope>(<biblScope unit="issue">2</biblScope>):<biblScope unit="page">158-168</biblScope>. <ptr type="web">https://doi.org/10.1056/NEJMra1703481</ptr></bibl>
	<bibl>. <author>Tadano H, Torigoe T</author>. <title level="a">Immune-related adverse events of immune checkpoint inhibitors</title>. <title level="j">Nihon Rinsho Meneki Gakkai Kaishi</title>. <date>2017</date>;<biblScope unit="volume">40</biblScope>(<biblScope unit="issue">2</biblScope>):<biblScope unit="page">102-108</biblScope>. <ptr type="web">https://doi.org/10.2177/jsci.40.102</ptr></bibl>
	<bibl>. <author>Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS</author>. <title level="a">Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology</title>. <title level="j">J Natl Compr Canc Netw</title>. <date>2019</date>;<biblScope unit="volume">17</biblScope>(<biblScope unit="issue">3</biblScope>):<biblScope unit="page">255-289</biblScope>. <ptr type="web">https://doi.org/10.6004/jnccn.2019.0013</ptr></bibl>
	<bibl>. <author>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S</author>. <title level="a">Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline</title>. <title level="j">Journal Clin Oncol</title>. <date>2018</date>;<biblScope unit="volume">36</biblScope>(<biblScope unit="issue">17</biblScope>):<biblScope unit="page">1714-1768</biblScope>. <ptr type="web">https://doi.org/10.1200/jco.2017.77.6385</ptr>.</bibl>
	<bibl>. <author>Kagamu H, Yamaguchi O, Todo M, Tamaki S.</author> <title level="a">チームで取り組む免疫チェックポイン ト阻害薬治療 [A team approach to immune checkpoint inhibitor therapy]</title>. <pubPlace>Tokyo, Japan</pubPlace>: <publisher>Chugai-Igakusha</publisher>; <date>2019</date>.</bibl>
	<bibl>. <author>Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K</author>. <title level="a">Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer</title>. <title level="j">JAMA Oncol</title>. <date>2018</date>;<biblScope unit="volume">4</biblScope>(<biblScope unit="issue">3</biblScope>):<biblScope unit="page">374-378</biblScope>. <ptr type="web">https://dx.doi.org/10.1001/jamaoncol.2017.2925</ptr></bibl>
	<bibl>. <author>Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G</author>. <title level="a">Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis</title>. <title level="j">J Immunother</title>. <date>2020</date>;<biblScope unit="volume">43</biblScope>(<biblScope unit="issue">1</biblScope>):<biblScope unit="page">1-7</biblScope>. <ptr type="web">https://doi.org/10.1097/CJI.0000000000000300</ptr></bibl>
	<bibl>. <author>Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A</author>. <title level="a">Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper</title>. <title level="j">Ann Oncol</title>. <date>2016</date>;<biblScope unit="volume">27</biblScope>(<biblScope unit="issue">4</biblScope>):<biblScope unit="page">559-574</biblScope>. <idno>doi:10.1093/annonc/mdv623</idno></bibl>
	<bibl>. <author>Hayashi C, Kokufu H</author>. <title level="a">The status of nursing practice for cancer patients receiving chemotherapy and factors related to the practice of nursing</title>. <title level="j">J Jpn Soc Cancer Nurs</title>. <date>2010</date>;<biblScope unit="page">24</biblScope>(<biblScope unit="issue">3</biblScope>);<biblScope unit="page">33-44</biblScope>.</bibl>
	<bibl>. <author>Moto N.</author> <title level="a">チーム医療の現状と今後の展望 [Current status and prospects of the team approach to medicine]</title>. <title level="j">J Jpn Soc Clin Oncol</title>. <date>2014</date>;<biblScope unit="volume">49</biblScope>(<biblScope unit="issue">2</biblScope>);<biblScope unit="page">489-492</biblScope>.</bibl>
	<bibl>. <author>Melnyk BM, Fineout-Overholt E, Feinstein NF, Li H, Small L, Wilcox L, Kraus R</author>. <title level="a">Nurses&apos; perceived knowledge, beliefs, skills, and needs regarding evidence-based practice: Implications for accelerating the paradigm shift</title>. <title level="j">Worldviews Evid-Based Nurs</title>. <date>2004</date>;<biblScope unit="volume">1</biblScope>(<biblScope unit="issue">3</biblScope>):<biblScope unit="page">185-193</biblScope>. <ptr type="web">https://doi.org/10.1111/j.1524-475X.2004.04024.x</ptr></bibl>
	<bibl>. <orgName>Ministry of Health, Labour and Welfare</orgName>. <title level="a">Designated cancer hospital</title>. <ptr type="web">https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/gan/gan_byoin.htm l</ptr>. Accessed <date>2 August 2020</date>.</bibl>
	<bibl>. <orgName>Ministry of Health, Labour and Welfare</orgName>. [<title level="a">Guidelines for the promotion of optimal use</title>]. <ptr type="web">https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000162318.pdf</ptr>. Accessed <date>1 October 2022</date>.</bibl>
	<bibl>. <author>Oda T</author>. [<title level="m">The Fundamentals of Social Research Methods</title>]. <pubPlace>Tokyo, Japan</pubPlace>: <publisher>Pleiades Publishing Co., Ltd</publisher>.; <date>2017</date>.</bibl>
	<bibl>. <title level="a">Nivolumab [Guidelines for Optimal Use]</title>. <pubPlace>New York, NY</pubPlace>: <publisher>Bristol-Myers Squibb Company</publisher>; <date>2014</date>.</bibl>
	<bibl>. <title level="a">Pembrolizumab [Guidelines for Optimal Use]</title>. <pubPlace>Kenilworth, NJ</pubPlace>: <publisher>Merck &amp; Co., Inc</publisher>; <date>2017</date>.</bibl>
	<bibl>. <author>Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK</author>. <title level="a">Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis</title>. <title level="j">JAMA Oncol</title>. <date>2018</date>;<biblScope unit="volume">4</biblScope>(<biblScope unit="issue">12</biblScope>):<biblScope unit="page">1721-1728</biblScope>. <ptr type="web">https://doi.org/10.1001/jamaoncol.2018.3923</ptr>.</bibl>
	<bibl>. <author>Davies M, Duffield EA</author>. <title level="a">Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events</title>. <title level="j">Immunotargets Ther.</title> <date>2017</date>;<biblScope unit="volume">6</biblScope>:<biblScope unit="page">51-71</biblScope>. <ptr type="web">https://doi.org/10.2147/ITT.S141577</ptr></bibl>
	<bibl>. <author>El Majzoub I, Qdaisat A, Thein KZ, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK</author>. <title level="a">Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center</title>. <title level="j">Ann Emerg Med</title>. <date>2019</date>;<biblScope unit="volume">73</biblScope>(<biblScope unit="issue">1</biblScope>):<biblScope unit="page">79-87</biblScope>. <ptr type="web">https://doi.org/10.1016/j.annemergmed.2018.04.019</ptr></bibl>
	<bibl>. <author>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S</author>. <title level="a">Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy</title>: <publisher>American Society of Clinical</publisher> <title level="a">Oncology clinical practice guideline</title>. <title level="j">J Clin Oncol</title>. <date>2018</date>;<biblScope unit="volume">36</biblScope>(<biblScope unit="issue">17</biblScope>):<biblScope unit="page">1714-1768</biblScope>. <ptr type="web">https://doi.org/10.1200/jco.2017.77.6385</ptr></bibl>
	<bibl>. <author>Kurata T, Yosioka H, Kaneda T</author>. <title level="a">肺がん化学療法 副作用マネジメント [Side effect management for lung cancer chemotherapy]</title>. <pubPlace>Tokyo</pubPlace>: <publisher>Medical View Co., Ltd</publisher>.; <date>2019</date>.</bibl>
	<bibl>. <author>Prochaska JO, Velicer WF</author>. <title level="a">The transtheoretical model of health behavior change</title>. <title level="j">Am J Health Promot</title>. <date>1997</date>;<biblScope unit="volume">12</biblScope>(<biblScope unit="issue">1</biblScope>):<biblScope unit="page">38-48</biblScope>. <idno>https://doi.org/10.4278/0890-1171-12.1.38</idno>. <idno>PMID: 10170434</idno></bibl>
	<bibl>. <orgName>Japanese Nursing Association</orgName>. <title level="m">Nursing Statistics</title>. <ptr type="web">https://www.nurse.or.jp/home/statistics/index.html</ptr>. Accessed <date>27 January 2021</date>.</bibl>
	<bibl>. <author>Kikuchi A, Harada T</author>. <title level="a">A study on the measurement of professional autonomy in nursing</title>. <title level="j">Bulletin of the Education Faculty, Shizuoka University. Liberal Arts and Social Sciences Series</title>. <date>1996</date>;<biblScope unit="volume">47</biblScope>:<biblScope unit="page">241-254</biblScope>.</bibl>
	<bibl>. <orgName>The Japanese Respiratory Society</orgName>. <title level="a">薬剤性肺障害の診断・治療の手引き短縮版 2013 [Guide to the diagnosis and treatment of drug-induced lung disorders shortened edition</title> <date>2013</date>]. <ptr type="web">https://www.jrs.or.jp/uploads/uploads/files/photos/1049.pdf</ptr>. Accessed <date>20 January 2021</date>.</bibl>
	<bibl>. <author>Wood LS, Moldawer NP, Lewis C</author>. <title level="a">Immune checkpoint inhibitor therapy: Key principles when educating patients</title>. <title level="j">Clin J Oncol Nurs</title>. <date>2019</date>;<biblScope unit="volume">23</biblScope>(<biblScope unit="issue">3</biblScope>):<biblScope unit="page">271-280</biblScope>. <ptr type="web">https://doi.org/10.1188/19.CJON.271-280</ptr>.</bibl>
	<bibl>. <author>McGettigan S, Rubin KM</author>. <title level="a">PD-1 inhibitor therapy: Consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events</title>. <title level="j">Clin J Oncol Nurs</title>. <date>2017</date>;<biblScope unit="volume">21</biblScope>(<biblScope unit="issue">4</biblScope> <note>Suppl</note>):<biblScope unit="page">42-51</biblScope>. <ptr type="web">https://doi.org/10.1188/17.CJON.S4.42-51</ptr></bibl>
	<bibl>. <author>Londoño M, Reig M</author>. <title level="a">Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors</title>. <title level="j">Cancers (Basel)</title>. <date>2020</date>;<biblScope unit="volume">12</biblScope>(<biblScope unit="issue">11</biblScope>):<biblScope unit="page">3446</biblScope>. <ptr type="web">https://doi.org/10.3390/cancers12113446</ptr></bibl>

		</listBibl>
	</back>
	</text>
</TEI>
